Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRestructuring CostsSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Capricor Therapeutics (CAPR) Shares Outstanding (Diluted Average) (2016 - 2025)

Historic Shares Outstanding (Diluted Average) for Capricor Therapeutics (CAPR) over the last 9 years, with Q3 2025 value amounting to $45.7 million.

  • Capricor Therapeutics' Shares Outstanding (Diluted Average) rose 3815.67% to $45.7 million in Q3 2025 from the same period last year, while for Sep 2025 it was $45.7 million, marking a year-over-year increase of 3815.67%. This contributed to the annual value of $35.2 million for FY2024, which is 3151.9% up from last year.
  • Per Capricor Therapeutics' latest filing, its Shares Outstanding (Diluted Average) stood at $45.7 million for Q3 2025, which was up 3815.67% from $45.7 million recorded in Q2 2025.
  • Capricor Therapeutics' Shares Outstanding (Diluted Average)'s 5-year high stood at $45.7 million during Q3 2025, with a 5-year trough of $22.2 million in Q1 2021.
  • Its 5-year average for Shares Outstanding (Diluted Average) is $29.5 million, with a median of $25.3 million in 2023.
  • As far as peak fluctuations go, Capricor Therapeutics' Shares Outstanding (Diluted Average) surged by 5263.93% in 2021, and later soared by 397.24% in 2023.
  • Over the past 5 years, Capricor Therapeutics' Shares Outstanding (Diluted Average) (Quarter) stood at $23.1 million in 2021, then grew by 6.34% to $24.6 million in 2022, then rose by 9.06% to $26.8 million in 2023, then skyrocketed by 31.52% to $35.2 million in 2024, then rose by 29.81% to $45.7 million in 2025.
  • Its last three reported values are $45.7 million in Q3 2025, $45.7 million for Q2 2025, and $45.6 million during Q1 2025.